AAA
RARE icon

Affinity Asset Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Affinity Asset Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,000
Closed -$1.73M – 115
2025
Q4 		$1.73M Buy
+75,000
New +$2.47M 0.1% 82

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Affinity Asset Advisors's RARE Position: Q1 2026 in Review

Affinity Asset Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 75,000 shares — an estimated $1.73M sold.

Affinity Asset Advisors first reported a position in RARE in Q4 2025 and held it in 1 quarter. The position peaked at $1.73M in Q4 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Affinity Asset Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Affinity Asset Advisors sold 75,000 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.73M.
  • Affinity Asset Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and held it in 1 quarter.
  • Affinity Asset Advisors's Ultragenyx Pharmaceutical position peaked at $1.73M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.